24th week of 2014 patent applcation highlights part 55 |
Patent application number | Title | Published |
20140162877 | BIO-STIMULANT FOR IMPROVED PLANT GROWTH AND DEVELOPMENT - A bio-stimulant composition for obtaining improved plant growth, either combined or uncombined with urea and/or other agricultural compounds, as well of methods of producing and using said composition. | 2014-06-12 |
20140162878 | SYNERGISTIC WEED CONTROL FROM APPLICATIONS OF AMINOCYCLOPYRACHLOR AND PICLORAM - Disclosed herein are herbicidal compositions comprising a synergistically herbicidal effective amount of (a) aminocyclopyrachlor, or an agriculturally acceptable salt or ester thereof, and (b) picloram, or an agriculturally acceptable salt or ester thereof. Also disclosed herein are methods of controlling undesirable vegetation, which comprise applying to vegetation or an area adjacent the vegetation or applying to soil or water to prevent the emergence or growth of vegetation (a) aminocyclopyrachlor, or an agriculturally acceptable salt or ester thereof, and (b) picloram, or an agriculturally acceptable salt or ester thereof, wherein (a) and (b) are each added in an amount sufficient to produce a synergistic herbicidal effect. | 2014-06-12 |
20140162879 | SYNERGISTIC WEED CONTROL FROM APPLICATIONS OF AMINOCYCLOPYRACHLOR AND 2,4 DICHLOROPHENOXYACETIC ACID (2,4-D) - Disclosed herein are herbicidal compositions comprising a synergistically herbicidal effective amount of (a) aminocyclopyrachlor, or an agriculturally acceptable salt or ester thereof, and (b) 2,4-D, or an agriculturally acceptable salt or ester thereof. Also disclosed herein are methods of controlling undesirable vegetation, which comprise applying to vegetation or an area adjacent the vegetation or applying to soil or water to prevent the emergence or growth of vegetation (a) aminocyclopyrachlor, or an agriculturally acceptable salt or ester thereof, and (b) 2,4-D, or an agriculturally acceptable salt or ester thereof, wherein (a) and (b) are each added in an amount sufficient to produce a synergistic herbicidal effect. | 2014-06-12 |
20140162880 | Controlled Release Granules - The present invention relates to a controlled release granule technology, methods of preparing such a granule and methods for using the granule in the control of pests. | 2014-06-12 |
20140162881 | USE OF RIBOSE TO ENHANCE PLANT GROWTH - The present invention to methods a compositions for supplementing the soil/diet of plants in order to enhance plant growth, yield, hardening, as well as the recovery of plants which undergo transplantation. The present invention provides ribose and other pentose sugars and their derivatives, alone or in combination with other carbohydrates, electrolytes, minerals, enzymes, micronutrients, macronutrients, or other ingredients to enhance plant growth, yield, hardening, and aid in the recovery during and following transplantation | 2014-06-12 |
20140162882 | CABLE TERMINATION FOR HIGH VOLTAGE POWER CABLES COOLED BY A GASEOUS CRYOGEN - A cable termination utilizing liquid and gaseous cryogen. The liquid cryogen maintains cryogen temperatures of all dielectric surfaces exposed to gaseous cryogen and to high voltage potential. The invention further includes capacitive grading, minimizing the electric field on the surface of the bushing in the vapor phase of the cryogen used in the liquid cryogen compartment. The cross-section of the conductor within the cable termination is adjusted along its axis enabling thermal optimization for reduction in the loss of liquid cryogen. Heat sink, for helium gas cooling of superconducting power devices, is surrounded by a metal of high thermal conductivity and placed near the area needed to be cooled. Cryogenic gaseous coolant flows through two tubes connected to the heat sink. Fins inside heat sink increase metal surface in contact with the coolant. The coolant flows from first tube, passes through the finned are and exits through the second tube. | 2014-06-12 |
20140162883 | ARRANGEMENT WITH AT LEAST ONE SUPERCONDUCTIVE CABLE - An arrangement is provided at least one superconductive cable ( | 2014-06-12 |
20140162884 | HIGH TEMPERATURE SUPERCONDUCTIVE FILMS AND METHODS OF MAKING THEM - Described is a superconductive layered structure and an article including this superconductive layered structure on a substrate structure. The superconductive layered structure comprises a stack including at least one bi-layered assembly formed by first and second layers of similar superconducting material compositions, the second layer being superconductive at predetermined temperature condition, the first layer being a substantially thin layer and having a c lattice parameter selected in accordance with those of the substrate structure and the second layer, such that said first layer is non-superconductive at said predetermined temperature condition thereby allowing the second superconductive layer to be desirably thick to provide high critical current density of the superconductive layer. | 2014-06-12 |
20140162885 | Bead Emulsion Nucleic Acid Amplification - Disclosed are methods for nucleic acid amplification wherein nucleic acid templates, beads, and amplification reaction solution are emulsified and the nucleic acid templates are amplified to provide clonal copies of the nucleic acid templates attached to the beads. Also disclosed are kits and apparatuses for performing the methods of the invention. | 2014-06-12 |
20140162886 | METHODS AND MATERIALS FOR ASSESSING ALLELIC IMBALANCE - Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided. | 2014-06-12 |
20140162887 | METHODS OF USING GENE EXPRESSION SIGNATURES TO SELECT A METHOD OF TREATMENT, PREDICT PROGNOSIS, SURVIVAL, AND/OR PREDICT RESPONSE TO TREATMENT - Methods and compositions for determining and/or predicting a response to a therapy, prognosis of a cancer subject or survival of a cancer and kits for performing the same are described herein. | 2014-06-12 |
20140162888 | CIRCULATING BIOMARKERS FOR DISEASE - Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA. | 2014-06-12 |
20140162889 | COMPOSITION OR KIT FOR MAKING A PROGNOSIS OF LIVER CANCER, AND METHOD FOR MAKING A PROGNOSIS OF LIVER CANCER - The present disclosure provides a marker for predicting prognosis of liver cancer, a composition or kit for predicting prognosis of liver cancer, preferably, a composition or kit for predicting prognosis of liver cancer for predicting the prognosis according to the stage of liver cancer. The marker, composition or kit, and method of the present disclosure make it possible to effectively predict prognosis of liver cancer, preferably, prognosis of liver cancer according to stage. | 2014-06-12 |
20140162890 | METHODS FOR PREPARING MONOCLONAL ANTIBODIES RECOGNIZING GLYCAN BINDING SITE AS AN EPITOPE - The present disclosure relates to a method for producing a monoclonal antibody that binds to an epitope for the glycan binding site of a glycoprotein. According to the present disclosure, a monoclonal antibody that recognizes the glycan binding site of a glycoprotein as an epitope can be produced in a relatively simple and economic manner, and a monoclonal antibody having high sensitivity and specificity for the glycan binding site of a glycoprotein can be produced. The monoclonal antibody produced according to the present disclosure can be effectively used as an agent for diagnosing or treating various diseases associated with a change in glycan structure or glycan expression level. | 2014-06-12 |
20140162891 | METHODS AND MATERIALS FOR DETECTION, DIAGNOSIS AND MANAGEMENT OF OVARIAN CANCER - The subject invention concerns methods using a panel of proteins to detect, diagnose, and monitor therapy during treatment of ovarian cancer in a female patient. The proteins were identified using proteomics analyses of plasma samples obtained preoperatively from ovarian cancer patients versus those of healthy control women. Such a panel has utility for the diagnosis of ovarian cancer, screening for ovarian cancer and possibly therapeutic monitoring. | 2014-06-12 |
20140162892 | Parallel polymer sequencing mothods - The present invention relates to a method of sequencing a target polynucleotide by enzymatic and/or chemical means. The sequencing method includes a method for characterizing multiple alleles in a sample, a method of calculating confidence levels in ascertained sequences, a method for comparing polynucleotide sequences and a method of resolving ambiguities in a polynucleotide sequence. It also provides methods for appropriately preparing samples, for immobilising template molecules, for organising the template molecules and to conduct the sequencing of many molecules in parallel. The method involves analysing molecules as members of an array. Many target polynucleotides or many segments of a single target polynucleotide can be sequenced simultaneously. In a preferred embodiment the method involves analysing individual molecules within an array and base calls are based on the signals from two or more molecules. A method to prevent non-specific signal in sequencing is also provided. The invention is readily automated, both for small-scale and large-scale operation and relevant algorithms and the composition of kits and systems are provided. | 2014-06-12 |
20140162893 | Aptamer Coated Measurement and Reference Electrodes and Methods Using Same for Biomarker Detection - A device for identifying the presence of a specific target molecule or biomarker by the detection of a change in an electrical property includes a measurement sensor | 2014-06-12 |
20140162894 | METHODS AND COMPOSITIONS FOR SCREENING AND TREATING DEVELOPMENTAL DISORDERS - This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder. | 2014-06-12 |
20140162895 | SYSTEM, COMPUTER PROGRAM AND METHOD FOR DETERMINING BEHAVIOR OF THYROID TUMOR - The invention provides a system adapted to a method for determining behavior of thyroid tumor. The system comprises a processor, and a memory, under control of said processor, including software instructions adapted to enable the system to perform operations. | 2014-06-12 |
20140162896 | COMPOSITIONS AND METHODS FOR GENOTYPING CES1 GENETIC VARIANTS AND USE THEREOF - The invention features compositions and methods that are useful for genotyping CES1 isoforms (CES1A1, CES1A2, CES1A3). The ability to specifically genotype one or more CES1 isoforms (e.g. CES1A1) is useful for assessing drug metabolism in a subject and guiding treatment selection. | 2014-06-12 |
20140162897 | TRANSPOSON END COMPOSITIONS AND METHODS FOR MODIFYING NUCLEIC ACIDS - The present invention provides methods, compositions and kits for using a transposase and a transposon end for generating extensive fragmentation and 5′-tagging of double-stranded target DNA in vitro, then using a DNA polymerase for generating 5′- and 3′-tagged single-stranded DNA fragments without performing a PCR amplification reaction, wherein the first tag on the 5′-ends exhibits the sequence of the transferred transposon end and optionally, an additional arbitrary sequence, and the second tag on the 3′-ends exhibits a different sequence from the sequence exhibited by the first tag. The method is useful for generating 5′- and 3′-tagged DNA fragments for use in a variety of processes, including processes for metagenomic analysis of DNA in environmental samples, copy number variation (CNV) analysis of DNA, and comparative genomic sequencing (CGS), including massively parallel DNA sequencing (so-called “next-generation sequencing.) | 2014-06-12 |
20140162898 | Method for Detecting Variations in Nucleic Acid Sequences - The present invention relates to a method and a kit for detecting nucleic acid sequence variation using melting curve analysis, especially relates to a method and a kit for detecting nucleic acid sequence variation by melting curve analysis using self-quenched probe. Said method provides the characteristics of the self-quenched probe employed, as well as the corresponding nucleic acid amplification conditions, so that the probe can bind to the amplified target sequence, and variations of the target sequence can be detected by melting curve analysis. The present invention also encompasses a kit assembled according to the method described. | 2014-06-12 |
20140162899 | CANCER PROGRESSION OBSERVATION INDEX GENE GROUP AND METHOD OF DETECTING THE GENE GROUP - Provided are a cancer progression observation index gene group and a method of detecting the gene group. The gene group includes cancer progression observation index genes increased or decreased when high- or low-dose radiation is performed on a mouse in which an oncogene is inserted into a thymocyte, for example, Itgb3 and Igf1 increased due to low-dose radiation to suppress the conversion of the thymocyte into a cancer cell, and Itga4, Itgb1, Itgav, Itga6, Itgb4, Raf, Myc, Fos, Trp53 and Apaf1 decreased due to high-dose radiation to stimulate the conversion of the thymocyte into a cancer cell. The gene group and the method may be used to clearly define a cancer progression observation index specifically responding to radiation. | 2014-06-12 |
20140162900 | METHOD FOR HIGH-THROUGHPUT SCREENING OF COMPOUNDS AND COMBINATIONS OF COMPOUNDS FOR DISCOVERY AND QUANTIFICATION OF ACTIONS, PARTICULARLY UNANTICIPATED THERAPEUTIC OR TOXIC ACTIONS, IN BIOLOGICAL SYSTEMS - The invention enables high-throughput screening of compounds in living systems to detect unanticipated or unintended biological actions. The invention also allows for screening, detection, and confirmation of new indications for approved drugs. Screening and detection of toxic effects of compounds also can be achieved by using the methods of the invention. The methods comprise administering isotope-labeled substrates to a living system so that the label is incorporated into molecules in a manner that reveals flux rates through metabolic pathways thought to be involved in a disease. Comparisons between living systems exposed to compounds and living systems not so exposed reveals the effects of the compounds on the flux rates through the metabolic pathways. Combinations or mixtures of compounds can be systematically screened to detect unantidpated or unintended biological actions, including synergistic actions, in the same manner. | 2014-06-12 |
20140162901 | NEEDLE ARRAY ASSEMBLY AND METHOD FOR DELIVERING THERAPEUTIC AGENTS - A fluid delivery device includes an array of needles, each in fluid communication with a respective reservoir. Respective actuators are coupled so as to be operable to drive fluid from the reservoirs via needle ports. Each needle can have a plurality of ports, and the ports can be arranged to deliver a substantially equal amount of fluid at any given location along its length. A driver is coupled to the actuators to selectively control the rate, volume, and direction of flow of fluid through the needles. The device can simultaneously deliver a plurality of fluid agents along respective axes in solid tissue in vivo. If thereafter resected, the tissue can be sectioned for evaluation of an effect of each agent on the tissue, and based on the evaluation, candidate agents selected or deselected for clinical trials or therapy, and subjects selected or deselected for clinical trials or therapeutic treatment. | 2014-06-12 |
20140162902 | Cell-Based Materials and Methods for Defining Pharmacogenetic Differences in Drug Metabolism - Cell lines harboring a range of polymorphisms using recombinant cytochrome P450 or other chemical-metabolizing enzymes in a parent cell line that is minimally expressing or devoid of its own cytochrome P450 protein or other chemical-metabolizing enzymes of interest can be placed into an array format to enable high throughput screening of one or more chemicals for CYP450 or other enzyme-dependent metabolism (FIG. | 2014-06-12 |
20140162903 | Metabolite Biomarkers For Forecasting The Outcome of Preoperative Chemotherapy For Breast Cancer Treatment - The present disclosure relates to a panel of metabolite species that is useful for forecasting the outcome of preoperative chemotherapy for the treatment of breast cancer, including methods for identifying and using such metabolite species that can be measured in biological samples taken before treatment. In preferred embodiments, a method of forecasting a treatment outcome before subjecting a breast cancer patient to preoperative chemotherapy is disclosed that includes measuring the concentration of at least one metabolite species in a sample of a biofluid taken from the breast cancer patient before preoperative chemotherapy treatment. | 2014-06-12 |
20140162904 | Library of Cells That Produce Antibodies That Comprise Non-Naturally Paired IGH and IGL Variable Domains - A method for producing a library of engineered-antibody producing cells is provided. In certain cases, the method includes isolating nucleic acid sequences encoding IgH variable regions and IgL variable regions from a plurality of antibody producing cells, and introducing the nucleic acids into host cells to obtain cells that produce antibodies comprising non-naturally paired IgH and IgL variable chains. | 2014-06-12 |
20140162905 | EVAPORATIVE EDGE LITHOGRAPHY OF A LIPOSOMAL DRUG MICROARRAY FOR CELL MIGRATION ASSAYS - Lipid multilayer structures are formed by evaporating a solvent from each of a plurality of lipid solutions thereby form the lipid multilayer structures. Each lipid solution comprises the solvent and one or more lipids. Each lipid multilayer structure is a microstructure comprising one or more lipids. | 2014-06-12 |
20140162906 | Pesticide Biomarker - Provided are methods, compositions and articles of manufacture for detecting biomarkers indicative of exposure of a mammal to organophosphate compounds. The interaction of such a biomarker with a receptor bound to a biopolymer results in an optical readout that reports the presence of the biomarker. | 2014-06-12 |
20140162907 | METHOD OF PRODUCING A SET OF MHC MOLECULES - The present invention relates to a method of producing a set of MHC molecules, and more precisely to a method of producing a set of MHC molecules which differ in their peptide bound in the binding groove. The method allows for parallel and rapid synthesis of different MHC molecules at high yields for each molecule. | 2014-06-12 |
20140162908 | BIO-CHIP - There is provided a bio-chip, including a fixing plate having a plurality of guide grooves formed in one surface thereof, a first substrate having a plurality of support plates inserted into the guide grooves, and a plurality of pillars protruded from one surface of the respective support plates, and having a biomaterial disposed thereon. | 2014-06-12 |
20140162909 | PRECIPITATED WEIGHTING AGENTS FOR USE IN WELLBORE FLUIDS - A method of formulating a wellbore fluid that includes precipitating a weighting agent from a solution; and adding the precipitated weighting agent to a base fluid to form a wellbore fluid is disclosed. Fluids and methods of formulating wellbore fluids that contain dispersant coated precipitated weighting agents are also disclosed. | 2014-06-12 |
20140162910 | Wellbore Servicing Compositions and Methods of Making and Using Same - A method of servicing a wellbore in a subterranean formation having one or more lost circulation zones comprising placing a wellbore servicing fluid comprising a sealing composition into the wellbore, wherein the sealing composition comprises a latex and an accelerator and wherein the latex, the accelerator or both are encapsulated with an encapsulation material. A wellbore servicing fluid comprising a latex and an accelerator wherein the latex, the accelerator, or both are encapsulated. | 2014-06-12 |
20140162911 | PROPPANT WITH COMPOSITE COATING - Proppants for hydraulic fracturing of oil and gas wells have a polymeric coating that is strengthened with reinforcing particulates that are reactive with, or chemically bonded to, the polymeric proppant coating. Preferably, these particulates are added into the coating during the coating process. In one embodiment, functionalized particulates are used that become grafted into the polymer of the proppant coating through the chemical functionality imparted to the particulates. If non-functionalized particulates are used, a coupling agent is preferably added to enhance the bond strength between the added particulates and the polymeric matrix of the proppant coating. | 2014-06-12 |
20140162912 | SWELLABLE POLYMER WITH CATIONIC SITES - The invention is directed to long lasting crosslinked water-soluble swellable polymers, methods for making same, and their uses. More particularly, the invention relates to a composition comprising expandable polymeric particles having cationic sites as well as labile crosslinkers and stable crosslinkers, said particle mixed with a fluid. A particularly important use is as an injection fluid in petroleum production, where the expandable polymeric particles are injected into a target zones in the reservoirs and when the heat and/or a suitable pH in the reservoir cause degradation of the labile crosslinker and when the particle expands, the cationic sites in the polymer adsorb to negative sites of the rock in the formation, thus diverting water to lower permeability regions and improving oil recovery. However, many other uses are possible. | 2014-06-12 |
20140162913 | CORROSION-INHIBITING LUBRICANT AND METHODS THEREFOR - Disclosed are corrosion-inhibiting lubricant compositions and methods of making and using the compositions. The lubricant compositions contain petroleum based components, corrosion-inhibiting additives and a cationic surfactant. In some embodiments, the lubricant compositions also contain nano diamonds. Under standard salt fog tests, compositions exhibited 120 or 168 hours to failure, or 0-20% rust at 192 hours. Under standard wear preventative characteristics tests, compositions exhibited as low as 0.55 mm wear. Also disclosed are a device and method for aerosol delivery of a corrosion-inhibiting lubricant. | 2014-06-12 |
20140162914 | Use of nanoscale materials in a composition for preventing symptoms of fatigue in the surface-closed structure of drive elements - A composition for prevention or reduction of fatigue damage, especially trench formation or micropitting, of the surfaces of drive elements, is provided that comprises 0.1 to 40% by weight of surface-modified nanoparticles, and 99.9 to 60% by weight of a carrier material suitable for application to the drive element surfaces. | 2014-06-12 |
20140162915 | Enhanced Lubricant Formulation - An enhanced lubricant formulation is provided as a formulation that improves upon existing lubricant systems by enhancing the tribological properties. The formulation utilizes inorganic fullerene-like tungsten disulfide (IF-WS | 2014-06-12 |
20140162916 | SLURRY TECHNIQUE FOR PRODUCING FLUOROPOLYMER COMPOSITES - A fluoropolymer composite comprising at least one fluoropolymer and particulate filler material is formed using a slurry process, in which the particulate filler material is first dispersed in a polar organic liquid, which is then combined with a suitable particulate fluoropolymer. The combination is dried to form a composite powder material. The composite powder material, with optional addition of another fluoropolymer, is processed to form a fluoropolymer composite body. The process can be carried out with either melt-processible or non-melt-processible fluoropolymers. | 2014-06-12 |
20140162917 | LUBRICATING COATING AGENT FOR PLASTIC WORKING AND METHOD FOR PRODUCING THE SAME - To provide a lubricating coating agent for plastic working, containing a non-black solid lubricating material, and a metal material coated with the agent, which enable highly difficult forging that has been conventionally difficult to practically apply to anything except lubricating coating films containing a black solid lubricant typified by molybdenum disulfide. The problems can be achieved by means of a lubricating coating agent for plastic working, which is characterized by containing, at 5 mass % or more in terms of solid content ratio in a coating film, a calcium sulfate hydrate with a particular scale-like crystal shape among calcium sulfate hydrates deposited by reacting a sulfuric acid or a sulfate with a calcium compound in water, and a metal material coated with the agent. | 2014-06-12 |
20140162918 | INDUSTRIAL GEAR LUBRICATING OIL COMPOSITION USED FOR RESISTING MICRO-PITTING - Provided is a micropitting corrosion resistant industrial gear lubricant composition, comprising: (A) at least a highly refined mineral oil, or synthetic oil or any combination of the above components; (B) at least a micropitting corrosion resistant additive; (C) at least an anti-wear additive; (D) at least a metal passivation additive; and (E) at least an anti-oxidation additive. | 2014-06-12 |
20140162919 | LUBRICATING OIL COMPOSITION FOR USE IN ALL TRANSMISSION SYSTEMS - Provided is a lubricant composition for a full transmission system, comprising: (A) at least an ashless dispersant; (B) at least a friction modifier; (C) at least a phosphorus-containing antiwear agent; (D) at least an antirust additive; (E) at least a sulfur-containing extreme-pressure additive; (F) at least a metal deactivation additive; (G) at least a viscosity index improver; (H) at least a pour-point depressant; and (I) at least a highly refined mineral oil with high viscosity index, or polyolefin synthetic oil, or ester synthetic oil, or any combination of the above components. The lubricant composition has excellent cleaning dispersity, frictional characteristic, antirust and anti-corrosive properties and extreme pressure abrasion resistance, meets US force standard MIL-PRF-2105E, and can be used for lubrication in various vehicle transmission systems. | 2014-06-12 |
20140162920 | Carboxylic Pyrrolidinones and Methods of Use Thereof - The present invention provides a compound comprising the reaction product of a hydrcarbyl substituted amine with an itaconate, such as an N-substituted 4-carboxypyrrolidin-2-one, and methods of employing the same in lubricating compositions. The lubricating compositions containing the N-substituted 4-carboxypyrrolidin-2-one are preferably intended to be employed in a method for lubricating a mechanical device, such as an automatic or manual transmission. However, it is envisioned that the compound can be employed in engine oil lubricants and any other type of functional fluid. | 2014-06-12 |
20140162921 | BIODERIVED BIODEGRADABLE LUBRICANT - A multi-purpose lubricant is described. In accordance with one implementation, a lubricant comprises food grade based oils substantially complying with USDA H-1 specifications for incidental contact with food, wherein at least one oil is selected from the group consisting of food grade plant oil, food grade poly-alpha-olefin, polyalkylene glycol, and mixtures thereof. In accordance with another implementation, a lubricant comprises canola oil, castor oil and a poly-alpha-olefin. In accordance with yet another implementation, a lubricant comprises canola oil, castor oil and a polyalkylene glycol. In accordance with yet another implementation, a lubricant comprises an oil substantially complying with USDA H-2 specification wherein the oil is at least one item selected from the group consisting of plant oil, poly-alpha-olefin, polyalkylene glycol, and mixtures thereof. In some implementations, the multi-purpose lubricant may be applied to areas of a bicycle chain. | 2014-06-12 |
20140162922 | LUBRICITY IMPROVER - The present invention relates to the use of a composition comprising a partial ester of a carboxylic acid and a polyhydric alcohol as a lubricity improver, wherein as the polyhydric alcohol use is made of a diglycerol composition which comprises at least 75.0 wt. % of diglycerol, wherein as the carboxylic acid use is made of a fatty acid composition which contains at least one C8-C22 fatty acid or a mixture of two or more thereof. | 2014-06-12 |
20140162923 | LUBRICATING OIL COMPOSITIONS CONTAINING STERICALLY HINDERED AMINES AS ASHLESS TBN SOURCES - Hindered amines useful as ashless TBN sources for lubricating oil compositions that are compatible with fluoroelastomeric engine seal materials, and lubricating oil compositions containing such compounds. | 2014-06-12 |
20140162924 | METHOD OF IMPROVING THE EFFICIENCY OF AUTOMOTIVE TRANSMISSIONS - A method for improving the fuel economy of an automobile is disclosed. The method involves lubricating an automotive transmission system with a lubricant composition containing (a) an oil of lubricating viscosity; (b) a viscosity modifying polymer comprising linear polymers characterized by the formula: | 2014-06-12 |
20140162925 | CLEANSING COMPOSITIONS AND PRODUCTS INCLUDING SOAP FLAKES AND METHODS FOR MAKING THE SAME - Cleansing compositions, products, and methods for making cleansing products are provided herein. In one example, a cleansing composition comprises a liquid detergent or cleanser. Soap flakes are dispersed in the liquid detergent or cleanser. | 2014-06-12 |
20140162926 | CLEANSING COMPOSITION WITH WHIPPED TEXTURE - A liquid cleansing composition comprising water in a sufficient amount to form a fluid composition; fatty acid soap; a divalent metal salt in an amount to provide a viscosity to entrain gas; and entrained gas to provide a specific gravity of not greater than 1.05 g/cm3. Optionally, a surfactant can also be included. The cleansing composition has a whipped texture. Also, a method of making the liquid cleansing composition. | 2014-06-12 |
20140162927 | Surface Cleaning and Coating Method and System - The cleaning formulation and method uses a polysilazane for superior cleaning and to create a protective coating with “easy clean” properties on numerous surface types, including metals, marine paints and gel-coat surfaces; cleaning and guarding them from the effects of all types of accretions, including two of the most pernicious—ice and diesel exhaust soot. The polysilazane is used with a cyclomethicone solvent, preferably pentacyclomethicone and/or hexacyclomethicone. The preferred method of application is by direct contact and application of the cleaning formulation to the treated surface via a microfiber cloth wrapped around a firm rubber blade or the like. | 2014-06-12 |
20140162928 | HIGH MOLECULAR WEIGHT POLYACRYLATES FOR ALUMINUM PROTECTION IN WAREWASH APPLICATIONS - A warewashing detergent composition is provided for use for in cleaning of alkaline sensitive metals such as aluminum or aluminum containing alloys. The compositions include alternatives to sodium tripolyphosphate and/or other phosphorous containing raw materials, while retaining cleaning performance and corrosion prevention. According to the invention, high molecular weight polyacrylates (polyacrylic acid homopolymers) with a molecular weight of at least about 5000 are used as corrosion inhibitors and can be included for aluminum protection in a number of different detergent compositions. | 2014-06-12 |
20140162929 | SOLUBLE POUCH COMPRISING HUEING DYE - The present application also relates to a water soluble pouch comprising at least one compartment, the pouch comprising a water soluble film encapsulating a composition, said composition comprising a negatively charged hueing dye and a solvent system comprising a primary solvent having a Hansen solubility (δ) of less than 29. | 2014-06-12 |
20140162930 | STRUCTURING WITH THREADS OF NON-POLYMERIC, CRYSTALLINE, HYDROXYL-CONTAINING STRUCTURING AGENTS - The need for a structurant premix that provides improved structuring of liquid compositions, while exhibiting less performance variation due to process variation or variation in ingredient levels, that is also particularly suitable for low water liquid compositions, is met through the use of an aqueous structuring premix comprising long threads of non-polymeric, crystalline, hydroxyl-containing structuring agent. | 2014-06-12 |
20140162931 | STRUCTURING WITH SHORT NON-POLYMERIC, CRYSTALLINE, HYDROXYL- CONTAINING STRUCTURING AGENTS - The need for a structurant premix that provides improved structuring of liquid compositions comprising high surfactant levels or hydrophobic ingredients is met through the use of an aqueous structuring premix comprising small particles of a non-polymeric, crystalline, hydroxyl-containing structuring agent. | 2014-06-12 |
20140162932 | AQUEOUS LIQUID FRAGRANCE COMPOSITION AND AQUEOUS LIQUID FRAGRANCE USING SAME - The present invention provides an aqueous liquid fragrance composition which contains a fragrance, gluconate, an anionic surfactant, a non-ionic surfactant and water, the sum of the amounts of the anionic surfactant and the non-ionic surfactant contained per 1 part by weight of the fragrance being 0.3 to 1.4 parts by weight, and also provides an aqueous liquid fragrance using the same. By containing gluconate, an anionic surfactant and a non-ionic surfactant in an aqueous liquid fragrance composition, this composition of the present invention makes it possible to reduce the amount of a surfactant for solubilizing the fragrance in water. In the present invention, reducing the amount of a surfactant for solubilizing the fragrance in water makes it possible to provide an aqueous liquid fragrance composition and aqueous liquid fragrance using the same whereby favorable volatility can be upheld during use, transparency can be maintained, and the appearance will not be adversely affected. | 2014-06-12 |
20140162933 | Methods and Compositions for Diagnosing, Prognosing, and Treating Neurological Conditions - This document provides methods and materials related to genetic variations of neurological disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Parkinson's disease. | 2014-06-12 |
20140162934 | NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS - The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery. | 2014-06-12 |
20140162935 | Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug - The embodiments provide Compound KC-8, N-1-[3-(oxycodone-6-enol-carbonyl-methyl-amino)-2,2-dimethyl-propylamine]-arginine-glycine-malonic acid, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug, Compound KC-8, that provides controlled release of oxycodone. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of oxycodone from the prodrug so as to attenuate enzymatic cleavage of the prodrug. | 2014-06-12 |
20140162936 | NEW CHYMASE BINDING COMPOUNDS AND MEDICAL USES THEREOF - The present invention relates to a polypeptide binding to a chymase (EC 3, 4, 21,39), wherein the polypeptide comprises or consists of an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDY(X | 2014-06-12 |
20140162937 | POLYMYXIN DERIVATIVES AND USES THEREOF - The present invention relates to a polymyxin derivative and to a combination product comprising at least two such derivatives. The invention further relates to a method for treating, alleviating or ameliorating an infection in a subject caused by a Gram-negative bacterium, by administering a therapeutically effective amount of a derivative according to the present invention to said subject; to a method for sensitizing Gram-negative bacteria to an antibacterial agent by administering, simultaneously or sequentially in any order a therapeutically effective amount of said antibacterial agent and a derivative according to the present invention to said subject; to methods for developing novel antibiotics; for reducing the nephrotoxicity, for improving the pharmacokinetic properties of natural polymyxins and octapeptins; and for sensitizing clinically important bacteria to a host defense mechanism complement present in serum. Finally, the invention relates to a process for preparing such polymyxin derivatives. | 2014-06-12 |
20140162938 | PEPTIDE COMPOUNDS AND METHODS OF PRODUCTION AND USE THEREOF - Peptide compounds based on the CAP37 protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptides. | 2014-06-12 |
20140162939 | ANTIBACTERIAL AGENTS: SALINAMIDE DERIVATIVES - The invention provides compounds of formula (I): | 2014-06-12 |
20140162940 | BIPARTITE INHIBITORS OF BACTERIAL RNA POLYMERASE: SAL-TARGET-INHIBITOR/NUCLEOSIDE-ANALOG-INHIBITOR CONJUGATES - The invention provides bipartite inhibitors of bacterial RNA polymerase that contain: (i) a first moiety that binds to the salinamide binding site of a bacterial RNA polymerase; (ii) a second moiety comprising a nucleoside analog; and (iii) a linker connecting said first and second moieties. | 2014-06-12 |
20140162941 | PROCESS FOR PREPARING BIOLOGICAL SAMPLES - Methods and compositions for preparation of a sample, including a sample to be analyzed for the presence of one or more pathogens. Transport of a non-diluted sample from an individual suspected of having the pathogen and transfer of the sample directly into a nucleic acid extraction buffer occurs in a single step. The process is an improvement over known methods because it provides accurate, rapid analysis that utilizes fewer steps and/or reagents from methods used in the art. In specific embodiments, it has one or more of the following characteristics: 1) it is a one-step process; 2) it eliminates dilution of the sample; 3) smaller sample sizes are employed; 4) fewer reagents are utilized; 5) transport media is not required; 6) less than 1 colony forming unit is required for detection; 7) fast; and 8) economic. | 2014-06-12 |
20140162942 | INHIBITION OF CYP3A DRUG METABOLISM - The present invention provides methods, pharmaceutical compositions, medicaments, and pharmaceutical kits that employ the use of boceprevir as a CYP3A4/5 inhibitor to improve the pharmacokinetics of therapeutic compounds metabolized by cytochrome P450 3A4/5 (CYP3A4/5) enzymes. | 2014-06-12 |
20140162943 | N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS - The disclosure provides N-terminus conformationally constrained compounds, which may comprise peptide mimetics and/or amino acid substitutions, which may be used in peptides, such as GLP-1 receptor agonist compounds, to induce β-turn secondary structure at the N-terminus. The N-terminus conformationally constrained compounds may be used for research purposes; to produce GLP-1 receptor agonist compounds having improved GLP-1 receptor binding activity, enzymatic stability, or in vivo glucose lowering activity; and to develop GLP-1 receptor agonist compounds which have fewer amino acid residues. The disclosure also provides GLP-1 receptor agonist compounds, such as exendins, exendin analogs, GLP-1(7-37), GLP-1(7-37) analogs, comprising the N-terminus conformationally constrained compounds. The compounds are useful for treating various diseases, such as diabetes and obesity. The disclosure also provides methods for chemically synthesizing the N-terminus conformationally constrained compounds. | 2014-06-12 |
20140162944 | CONTROLLED RELEASE PEPTIDE FORMULATIONS - The present invention relates to compositions forming a low viscosity mixture of: a) 20-80 wt. % of at least one diacyl glycerol and/or a tocopherol; b) 20-80 wt. % of at least one phosphatidyl choline (PC); c) 5-20 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) up to 20 wt. % polar solvent e) at least one peptide active agent; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations. | 2014-06-12 |
20140162945 | GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE ANALOGS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF - The present invention provides a GIP analog, which is derived from GIP (1-29, SEQ ID NO: 1), has both GLP-1 agonist activity and GIPR stimulation activity, and comprises an amino acid sequence represented by the following formula I: Tyr-A2-A3-Gly-Thr-Phe-A7-Ser-Asp-Tyr-Ser-A12-A13-A14-A15-Lys-A17-A18-A19-A20-A21-A22-A23-A24-Trp-Leu-A27-A28-A29-Y. The present invention also provides a pharmaceutical composition comprising the GIP analog and use thereof. | 2014-06-12 |
20140162946 | FORMULATIONS AND METHODS FOR WEIGHT LOSS AND BODY CONTOURING - Formulations and methods for weight loss and body contouring are disclosed. An illustrative formulation comprises human chorionic gonadotrophin (hCG) and resveratrol. An illustrative method for weight loss and body contouring comprises administering hCG and resveratrol sublingually. | 2014-06-12 |
20140162947 | Kruppel-like Factor 10 (KLF10) as a Biomarker of Endothelial Progenitor Cell Dysfunction - The use of Kruppel-like Factor (KLF10) as a diagnostic and prognostic tool for peripheral artery disease and other disease conditions associated with reduced angiogenesis or endothelial progenitor cell dysfunction such as diabetes and stent thrombosis. | 2014-06-12 |
20140162948 | FORMULATION FOR INCREASING BIOAVAILABILITY OF NEURTURIN - The present invention relates to formulations with protein growth factors, particularly neurturin as active ingredients and low molecular weight polyanionic excipients having increased bioavailability. | 2014-06-12 |
20140162949 | TREATMENT WITH HUMAN GROWTH HORMONE ANALOGUES - The present invention concerns an improved therapeutic regimen for GHD therapy. In particular, the invention concerns methods for bolus dose administration of a human growth hormone-XTEN (hGH-XTEN) fusion protein. | 2014-06-12 |
20140162950 | METHOD FOR INHIBITING PERITONEAL METASTASIS CAUSED BY GASTRIC CANCER CELLS - The present invention provides a method for inhibiting peritoneal metastasis caused by gastric cancer cells in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of a connective tissue growth factor (CTGF), wherein the CTGF binds to an integrin α3β1 of the gastric cancer cells. The present invention also provides a method for predicting peritoneal metastasis caused by gastric cancer cells in a subject comprising providing a peritoneal tissue from the subject; measuring a first expression amount of a connective tissue growth factor (CTGF) from the peritoneal tissue; and comparing the first expression amount to a reference expression amount of the CTGF from a non-peritoneal metastasis gastric cancer tissue. | 2014-06-12 |
20140162951 | ISOLATED NUCLEIC ACID MOLECULE ENCODING A NEUROTROPHIC GROWTH FACTOR - There is disclosed an isolated nucleic acid molecule encoding a human neurotrophic growth factor designated enovin and having the amino acid sequence illustrated in FIG. | 2014-06-12 |
20140162952 | ERAP1-DERIVED PEPTIDE AND USE THEREOF - Provided is a novel cancer-treating agent which can be used as a novel choice for the treatment of cancer. Specifically provided are: a peptide that inhibits binding of ERAP1 polypeptide to PHB2 polypeptide, which comprises a binding site of the ERAP1 polypeptide to the PHB2 polypeptide, and a pharmaceutical composition comprising the peptide. In addition, provided is a method for screening a drug candidate for treating and/or preventing cancer using inhibition of the binding of the ERAP1 polypeptide to PP1α polypeptide, PKA polypeptide or PKB polypeptide as an index. | 2014-06-12 |
20140162953 | USE OF INHALABLE POWDER FORMULATION COMPRISING GROWTH HORMONE FOR PREVENTING OR TREATING NMDA RECEPTOR HYPOFUNCTION-RELATED DISEASES - A use of an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease, a method for preventing or treating an NMDA receptor hypofunction-related disease in a subject, which comprises administering a therapeutically effective amount of an inhalable powder formulation comprising growth hormone (GH) to the subject in need thereof, and an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease comprising GH as an active ingredient are provided. | 2014-06-12 |
20140162954 | FUSION OF HUMAN GROWTH HORMONE AND ALBUMIN FORMULATION AND USES THEREOF - The present invention provides a method of treating a human patient in need of growth hormone therapy by periodically administering to the human patient for more than two weeks an effective amount of a composition comprising a pharmaceutically acceptable carrier and a fusion protein whose amino acid sequence is set forth as SEQ ID NO:1, so as to thereby treat the human patient. The present invention also provides a method of treating a human patient in need of growth hormone therapy by administering to the human patient, in a clinically effective regimen, a clinically effective dose of a composition comprising a pharmaceutically acceptable carrier and a fusion protein whose amino acid sequence is set forth as SEQ ID NO:1, wherein the clinically effective dose and clinically effective regimen are selected by a series of steps. | 2014-06-12 |
20140162955 | Antagonizing Heparin With Salicylamide Compounds And Histamine Blocking Agents - The present disclosure provides combinations of salicylamide compounds, or pharmaceutically acceptable salts thereof, and histamine blocking agents, or pharmaceutically acceptable salts thereof, for antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative. | 2014-06-12 |
20140162956 | POLYPEPTIDES - The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans. | 2014-06-12 |
20140162957 | LYOPHILIZED FORMULATION OF TAT-NR2B9C - The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. Such formulations are stable at room temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital. | 2014-06-12 |
20140162958 | Copolymer-1 Composition and Methods of Use - Disclosed herein are compositions that comprise copolymer-1 and an anesthetic agent. Also provided are methods that include the administration of a composition comprising copolymer-1 and an anesthetic agent. Such methods are useful for the treatment of multiple sclerosis; for reducing the occurrence and/or severity of the side effects associated with a therapeutic regimen comprising administration of copolymer-1; and for increasing patient compliance with a therapeutic regimen comprising administration of copolymer-1. | 2014-06-12 |
20140162959 | SUSPENSION TYPE TOPICAL FORMULATIONS COMPRISING CYCLIC DEPDIPEPTIDE - The invention relates to novel topical pharmaceutical compositions in which the active agent is a cyclic depsipeptide of formula (II) | 2014-06-12 |
20140162960 | Scaffold-Kinase Interaction Blockades and Uses Thereof in Treating Cancer - Aspects of the invention include compositions and methods for inhibiting the interaction between scaffold proteins and kinases. These compositions and methods find a number of uses including, for example, suppressing tumor growth and metastasis and reducing tumor size and number in a mammal with cancer. | 2014-06-12 |
20140162961 | COMPOSITIONS AND METHODS FOR TRANSPORT ACROSS THE BLOOD BRAIN BARRIER - Compositions and methods are provided including a transporter peptide derived from the loop2 domain of the neuronally-derived lynx1 protein which can be conjugated to an effector agent to form a transporter-effector complex for transport of the therapeutic effector agent to a target that is found across the blood brain barrier. | 2014-06-12 |
20140162962 | NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS - The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery. | 2014-06-12 |
20140162963 | Treatment of Constipation-Predominant Irritable Bowel Syndrome - The invention provides methods for treating a patient with constipation-predominant irritable bowel syndrome by administering a therapeutically effective dose of linaclotide. | 2014-06-12 |
20140162964 | USE IN BRAIN DEGENERATIVE DISEASES - Disclosed is a new use for sphingosine-1-phosphate (S1P) receptor agonists in the treatment of progressive dementia or brain degenerative diseases. | 2014-06-12 |
20140162965 | COMPOSITIONS FOR ORAL DRUG ADMINISTRATION - The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery in the form of a tablet. | 2014-06-12 |
20140162966 | NANOPARTICLES FOR DELIVERY OF LIGANDS - Disclosed is a nanoparticulate complex comprising an artificial phosphate receptor of formula (I): P-[L-[-N(CH | 2014-06-12 |
20140162967 | NOVEL PYRAZOLE COMPOUNDS - The present invention provides a compound of Formula II: | 2014-06-12 |
20140162968 | METHOD FOR SCREENING OF AGENT FOR TREATING OR PREVENTING OBESITY - The present invention relates to a method for screening and preparing an obesity prevention or treatment agent, and a method for preparing an obesity prevention or treatment agent. Being able to easily detect a substance that has a preventive and therapeutic effect on obesity, the present invention has a wide spectrum of applications in the research and medicine field in the prevention or treatment of obesity. | 2014-06-12 |
20140162969 | MICROSPHERES FOR TREATMENT OF BRAIN TUMOURS - There is provided a new use of microspheres comprising a water-insoluble, water-swellable polymer which is anionically charged at pH7, and electrostatically associated with the polymer, in releasable form, a cationically charged chemotherapeutic agent, in the manufacture of a composition for use in the treatment of a brain tumour, wherein in the treatment the composition is introduced into the brain and the chemotherapeutic agent is released from the microspheres, wherein the microspheres, when equilibrated in water at 37° C., comprise at least 40 wt % water based on weight of polymer plus water. Compositions comprising the microspheres and methods for the treatment of brain tumours are also provided. | 2014-06-12 |
20140162970 | Treating Cardiac Arrhythmias, Heart Failure, Peripheral Artery Disease and Stroke With Cyclopentyl-Triazolo-Pyrimidine or Derivative Thereof - The present invention relates to new methods for treating and/or preventing cardiac arrhythmias, heart failure, stroke and/or peripheral artery disease by administering a composition comprising triazolopyrimidine, or derivative or metabolite thereof. In particular, the present invention relates to methods for treating cardiac arrhythmias, heart failure, stroke and/or peripheral artery disease by administering CycloPentyl-TriazoloPyrimidine. | 2014-06-12 |
20140162971 | BROMODOMAIN INHIBITORS - The present invention provides for compounds of formula (I) | 2014-06-12 |
20140162972 | URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS - This disclosure relates to prodrugs of uridine diphosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those prodrugs of the UDP derivatives and methods of using those prodrugs or compositions in treating disorders that are responsive to ligands, such as agonists, of P | 2014-06-12 |
20140162973 | PALATABLE NUTRITIONAL COMPOSITION COMPRISING A NUCLEOTIDE AND/OR A NUCLEOSIDE AND A TASTE MASKING AGENT - The present invention relates to the use of a taste masking agent selected from the group of starch; cellulose; xanthan gum; gellan gum; alginate; galactomannans such as fenugreek, guar gum, tara gum, locust bean gum, and cassia gum; gum karaya; gum tragacanth; carrageenan; and mixture thereof, for improving one or more of mouth feel, taste, aftertaste and smell of a liquid aqueous nutritional composition comprising a nucleoside and/or a nucleotide. It also relates to a nutritional composition comprising an unsavoury nucleoside and/or nucleotide component, having improved sensory characteristics such as improved mouth feel, taste, aftertaste and smell. In particular, it relates to a composition comprising said unsavoury nucleoside and/or nucleotide component, in particular comprising an uridine-containing nucleoside and/or a nucleotide in combination with an unsavoury edible oil, such as a fish oil. | 2014-06-12 |
20140162974 | METHODS FOR MODULATION OF PHOSPHORUS AND FGF23 - Compositions and methods for decreasing phosphorus, decreasing cFGF23, or increasing iFGF23 in a subject. Such compositions and methods can be useful for treatment of conditions, disorders, or diseases associated with phosphorus or FGF23 disregulation. | 2014-06-12 |
20140162975 | VISCOELASTIC GEL FOR DERMATOLOGICAL USE - The invention relates to a polysaccharide gel of natural origin for dermatological use that comprises an aqueous solution of the polysaccharide of 0.1 to 5% by weight/volume, for example hyaluronic acid, and a viscous and strongly hydrophilic biocompatible alcohol at 0.5-5% by weight/volume, for example glycerol, and optionally the adjuvants that are commonly used in dermatology. The gel is prepared by mixing the polysaccharide solution and the strongly hydrophilic viscous alcohol before sterilizing the entire mixture by, for example, moist heat. | 2014-06-12 |
20140162976 | COMPOSITIONS COMPRISING HYDROXYTYROSOL AND CHONDROITIN AND USE THEREOF FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS - The present invention relates to novel compositions comprising hydroxytyrosol and chondroitin as well as to the use of these compositions as a medicament, in particular as a medicament for the treatment, co-treatment or prevention of inflammatory disorders. | 2014-06-12 |